T wo recent studies provide new clues to why people infected with human immunodeficiency virus (HIV) are at high risk -sometimes very high risk--for lymphoma.
One of the studies adds new data linking macrophages in HIV patients with the development of AIDS-related lymphoma (ARL). The other suggests that AIDS patients who develop lymphoma have higher levels of certain cytokines as early as 2 years before their diagnosis. The fi ndings could lead to new prevention and treatment strategies not only for ARL but also for other types of lymphoma, according to the researchers, who presented their fi ndings in April at the annual meeting of the American Association for Cancer Research (AACR).
"Because of the homogeneity of ARL, we can use its pathogenesis as a window into other types of lymphoma, which is a very heterogeneous disease," said Charles Rabkin, M.D. , senior investigator at the National Cancer Institute and author of the cytokine study.
Unlike most other lymphomas, ARL is usually high grade and metastatic at diagnosis; patients commonly die within weeks of diagnosis. It's a common cancer in AIDS patients but did not become an AIDSdefi ning disease until 1985, which suggested that it develops more slowly than other AIDS-related cancers such as Kaposi sarcoma. The simple explanation for its late appearance is that the more time that passes after HIV infection, the more likely one is to develop lymphoma, said Michael McGrath, M.D., Ph.D., a professor at the University of California, San Francisco, and senior author of the macrophage study. "The more complex explanation may involve the evolution of HIV in macrophages that harbor mutations."
Macrophages
Last year, a study by McGrath and Leanne Huysentruyt, Ph.D., assistant research scientist at UCSF, suggested that macrophages in ARL patients could be a haven for HIV, allowing the virus to develop resistance to standard antiviral treatments. In the study presented at AACR, their aim was to determine the prevalence of these HIV-infected macrophages in a larger sample population. Examining 150 ARL biopsy samples taken from 1984 to 2007, they found that after 1996, when highly active antiretroviral therapy (HAART) was introduced, approximately half of ARLs contained HIV-infected macrophages, compared with 26% in the pre-HAART era.
"This [fi nding] was surprising, as HAART targets HIV replication," Huysentruyt said. "But apparently HAART has little or no effect on the virus in macrophages."
Macrophages in general, and specifi cally HIV-infected macrophages in ARL patients, are long lived. "This suggests that HIV undergoes genetic changes in macrophages and that they serve as reservoirs for HIV," McGrath said. He hypothesizes that the macrophages, which resist antiretroviral drugs, enable the virus to mutate within them and drive ARL development.
If as many as half of ARL patients have tumor-specific HIV within infected macrophages, as the AACR study suggests, then macrophage-targeted drug therapy might be benefi cial, Huysentruyt said. "From our fi ndings, we believe that new drugs to target HIV-infected macrophages could be effective in treating ARLs and may also be necessary to wipe out HIV infection itself," she said.
McGrath is now working with a grant from the National Institute of Mental Health, 
Cytokines
Whereas McGrath's goal is to directly target macrophages, another anticancer strategy is to disrupt macrophage products -cytokines, such as interleukin 10 (IL-10) and IL-6 -and growth factors, such as vascular endothelial growth factor. Not only do these cytokines help cancer grow, but some also hyperstimulate B cells, driving B-cell proliferation and development of both lymphoma and HIV.
In the other ARL study presented at AACR, NCI's Rabkin and colleagues examined blood levels of 30 cytokines in 66 ARL patients from three prospective cohort studies. They found cytokines that were elevated as early as 2 years before ARL diagnosis. That means, Rabkin said, that to try to prevent ARL in the short term, "scientists could monitor cytokine levels of patients on HAART, along with CD4 and other biomarkers, and modify HAART drug combinations to see if that can alter cytokine levels."
In related research, Otoniel MartinezMaza, Ph.D., at the University of California, Los Angeles, investigated cytokine levels at 1, 3, and 5 years before a lymphoma diagnosis in AIDS patients. The fi ndings, not yet published, showed elevated levels "a long time" before diagnosis, he said. They also showed several elevated biomarkers for B-cell stimulation.
N E W S
Rabkin, Martinez-Maza, and others are also investigating polymorphisms in cytokine genes as an ARL risk factor. In a newly published study in AIDS with 160 ARL patients, Rabkin and Martinez-Maza examined variations in the gene for IL-10, an anti-infl ammatory cytokine that also stimulates B cells. Patients with two copies of a "low response" IL-10 gene variation, which predisposes them to have lower IL-10 levels, had a reduced risk of lymphoma. One possible explanation is that the B cells were not hyperstimulated by the low-response IL-10 variant, he said.
Researchers are also beginning to fi nd similarities between ARL and lymphoma in patients without HIV -AIDS. In a prospective study published last year in Blood , Martinez-Maza found elevated levels of some of the same cytokines found in ARL patients, as well as elevated IL-6 and IL-10, before diagnosis of non-Hodgkin lymphoma in healthy adults. In an ongoing study, using the Department of Defense's large serum repository, he and Lynn Levin, Ph.D., a geneticist at the Walter Reed Army Hospital in Washington, D.C., have identifi ed 600 individuals diagnosed with NHL in the general population. The researchers are now matching them with control subjects reaching back a decade before diagnosis and will analyze samples to see whether certain cytokines are elevated years before diagnosis in this population, as they are in ARL patients.
"We are beginning to fi nd some similarities between ARL and NHL profi les, and I think we will see more," Martinez-Maza said.
